Skip Navigation


Rheumatology Advance Access originally published online on May 28, 2009
Rheumatology 2009 48(8):906-910; doi:10.1093/rheumatology/kep129
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/8/906    most recent
kep129v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Radovits, B. J.
Right arrow Articles by Laan, R. F. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radovits, B. J.
Right arrow Articles by Laan, R. F. J. M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Missed opportunities in the treatment of elderly patients with rheumatoid arthritis

Beáta J. Radovits1, Jaap Fransen1, Agnes Eijsbouts2, Piet L. C. M. van Riel1 and Roland F. J. M. Laan1

1Department of Rheumatology, Radboud University Nijmegen Medical Centre and 2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.

Correspondence to: Beata J. Radovits, Department of Rheumatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Hp 470, 6500 HB Nijmegen, The Netherlands. E-mail: B.Radovits{at}reuma.umcn.nl; bradovits{at}hotmail.com


  Abstract

Objective. To investigate whether there is a difference in waiting time between indication and start of anti-TNF-{alpha} therapy in younger and older RA patients.

Methods. The study was carried out in the Nijmegen inception cohort of early RA. All patients meeting indications for anti-TNF-{alpha} therapy according to the Dutch reimbursement criteria were included in the analysis. Time from indication to start of anti-TNF-{alpha} therapy or censoring was calculated in all patients. Multivariable Cox regression analysis was used to investigate the influence of age at indication on the time to commencement of anti-TNF-{alpha} treatment. Hazard ratios were calculated for groups in age quartiles. The model was corrected for 28-joint disease activity score (DAS28), disease duration, gender, the Charlson comorbidity index and episodes of serious illnesses between indication and anti-TNF-{alpha} therapy or censoring.

Results. From the 487 eligible patients, 215 patients started anti-TNF-{alpha} treatment during their follow-up (44%). Age significantly influenced the time to receiving anti-TNF-{alpha} after first indication, adjusting for confounders (HR = 0.975/year, P < 0.001). The same analysis using age quartiles showed that the younger age groups had a higher chance of receiving anti-TNF-{alpha} treatment within an equal period of time than older patients [HR 2.67 (95% CI 1.64, 4.35); 2.30 (1.43, 3.71); 1.79 (1.14, 2.81) with increasing age; the eldest group as reference]. The eldest patients had significantly higher DAS28 values prior to anti-TNF-{alpha} treatment than younger patients.

Conclusion. Elderly RA patients were less likely to receive anti-TNF-{alpha} treatment within an equal period of time compared with younger patients, taking disease activity, disease duration and comorbidities into account.

KEY WORDS: Rheumatoid arthritis, Decision making, Elderly, Anti-TNF-{alpha} treatment, Indication

Submitted 18 November 2008; revised version accepted 21 April 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. T. C. van Hulst, M. C. W. Creemers, J. Fransen, L. C. Li, R. Grol, M. E. J. L. Hulscher, and P. L. C. M. van Riel
How to improve DAS28 use in daily clinical practice?--a pilot study of a nurse-led intervention
Rheumatology, January 18, 2010; (2010) kep407v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.